@article {Yeung526, author = {Yeung, Jennifer and Li, Wenjie and Holinstat, Michael}, editor = {Isom, Lori L.}, title = {Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases}, volume = {70}, number = {3}, pages = {526--548}, year = {2018}, doi = {10.1124/pr.117.014530}, publisher = {American Society for Pharmacology }, abstract = {Platelets are essential for clotting in the blood and maintenance of normal hemostasis. Under pathologic conditions such as atherosclerosis, vascular injury often results in hyperactive platelet activation, resulting in occlusive thrombus formation, myocardial infarction, and stroke. Recent work in the field has elucidated a number of platelet functions unique from that of maintaining hemostasis, including regulation of tumor growth and metastasis, inflammation, infection, and immune response. Traditional therapeutic targets for inhibiting platelet activation have primarily been limited to cyclooxygenase-1, integrin αIIbβ3, and the P2Y12 receptor. Recently identified signaling pathways regulating platelet function have made it possible to develop novel approaches for pharmacological intervention in the blood to limit platelet reactivity. In this review, we cover the newly discovered roles for platelets as well as their role in hemostasis and thrombosis. These new roles for platelets lend importance to the development of new therapies targeted to the platelet. Additionally, we highlight the promising receptor and enzymatic targets that may further decrease platelet activation and help to address the myriad of pathologic conditions now known to involve platelets without significant effects on hemostasis.}, issn = {0031-6997}, URL = {http://stonel.info/content/70/3/526}, eprint = {http://stonel.info/content/70/3/526.full}, journal = {Pharmacological Reviews} }